Picture of CVS Health logo

CVS — CVS Health News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapSuper Stock

CVS beats Q3 revenue, profit estimates, outlook raised; to split into two

CVS beats Q3 revenue, profit estimates, outlook raised; to split into two


Overview

  • US health solutions firm's Q3 revenue rose 5.4%, beating analyst expectations

  • Q3 adjusted EPS increased to $2.09, beating analyst expectations

  • Company raised full-year 2026 guidance for EPS and cash flow from operations

  • CVS to split in two, separating pharmacy business from insurance


Outlook

  • CVS raises full-year 2026 GAAP diluted EPS guidance to at least $6.98 from $6.84-$7.04

  • Company lifts 2026 adjusted EPS guidance to at least $8.20 from $7.90-$8.10

  • CVS increases 2026 cash flow from operations guidance to at least $15.5 bln from $11.5 bln


Result Drivers

  • HEALTH SERVICES GROWTH - Revenue in the Health Services segment rose 9.5%, driven by pharmacy drug mix and brand inflation, partly offset by pharmacy client price improvements

  • HEALTH CARE BENEFITS IMPROVEMENT - Adjusted operating income in the Health Care Benefits segment rose, mainly due to improved performance in the Government business

  • RETAIL PHARMACY PRESSURE - Pharmacy & Consumer Wellness revenue fell 2.0% due to regulatory-related price reductions, new generic drug introductions, and reimbursement pressure, partly offset by increased prescription volume and brand inflation


Company press release: ID:nPn9XhqbCa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$108.40 bln

$104.69 bln (19 Analysts)

Q3 Adjusted EPS

Beat

$2.09

$1.65 (24 Analysts)

Q3 EPS

$1.68


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for CVS Health Corporation is $112.00, about 22.5% above its November 3 closing price of $91.41

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 13 three months ago


Reuters Recommended Reads

  • Nov 3 - CVS Health explores splitting retail pharmacy, insurance businesses, FT reports

  • Nov 3 - Senior care provider InnovAge's Q1 revenue beats as participants increase

  • Nov 3 - Addus HomeCare Q3 adjusted EPS beats estimates; to acquire AccentCare personal care division


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on CVS Health

See all news